$0.98 -$0.02 (-2.5%)

04:00 PM EDT on 09/20/19

Trevena, Inc. (NASDAQ:TRVN)

CAPS Rating: 5 out of 5

Current Price $0.98 Mkt Cap $80.5M
Open $1.02 P/E Ratio 0.00
Prev. Close $1.00 Div. (Yield) $0.00 (0.0%)
Daily Range $0.97 - $1.02 Volume 499,186
52-Wk Range $0.43 - $2.00 Avg. Daily Vol. 17

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

32 Outperform
0 Underperform
 

All-Star Players

5 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:TRVN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

IBDvalueinvestin (97.61)
Submitted March 16, 2015

RA Capital - Peter Kolchinsky a Ph.D in Virology from Harvard has bought millions of shares within the last qtr. His track record suggests that TRVN will be a big winner.RA Capital posting third quarter returns of 51.5% and 1-year returns of… More

TSIF (99.97)
Submitted September 01, 2015

Trevena has some solid followers, but the froth after the Phase 2 data is excessive at this point. Cash burn high, investment "raise" needed before Phase III gets much traction. Well respected Barron's suggests target $20, so this one may get a bit… More

NASDAQ:TRVN VS S&P 500 (SPY)

NASDAQ:TRVN Summary

Fools bullish on NASDAQ:TRVN are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about TRVN.

Recs

0
Member Avatar superstar (99.95) Submitted: 10/10/2018 10:58:37 AM : Outperform Start Price: $0.91 NASDAQ:TRVN Score: +2.25

Loading up the truck!

Recs

0
Member Avatar btechrisk11 (< 20) Submitted: 4/15/2018 10:40:23 PM : Outperform Start Price: $1.63 NASDAQ:TRVN Score: -51.92

pain treatment up for approval that is a novel biased ligand for opioid receptor. Potential for opioid-like pain relief with less side effects. Its an injectable so limited to hospital use but could be big if approved.

Recs

0
Member Avatar CM0330 (< 20) Submitted: 7/18/2016 10:34:44 PM : Outperform Start Price: $6.67 NASDAQ:TRVN Score: -123.55

TRVN has the chance to revolutionize pain management, and how doctors administer medicine to deal with recovery for surgical procedures. WIth preliminary data from thier test trials looking strong, I look for the stock to break out in the low teens by early 2017, and potentially take off from there on once more positive data has been obtained.

Leaderboard

Find the members with the highest scoring picks in TRVN.

Score Leader

anchak

anchak (99.91) Score: +119.31

The Score Leader is the player with the highest score across all their picks in TRVN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
superstar 99.95 10/10/2018 Outperform 5Y $0.91 +7.38% +5.13% +2.25 1 Comment
rt83 22.39 9/12/2018 Outperform 5Y $1.63 -40.00% +3.33% -43.33 0 Comment
redfox18 99.90 3/21/2019 Outperform 5Y $1.77 -44.89% +5.57% -50.46 0 Comment
btechrisk11 < 20 4/16/2018 Outperform 1Y $1.63 -40.18% +11.74% -51.92 1 Comment
risktech 26.21 3/29/2018 Outperform 5Y $1.73 -43.64% +14.25% -57.90 0 Comment
sunvestor7 32.18 10/17/2017 Outperform 5Y $1.85 -47.30% +16.80% -64.10 0 Comment
retirebefore50 < 20 10/3/2018 Outperform 5Y $3.46 -71.79% +2.36% -74.15 0 Comment
manirg < 20 7/31/2017 Outperform 5Y $2.61 -62.64% +20.90% -83.54 0 Comment
Bigeric98 99.95 3/30/2017 Outperform 1Y $3.74 -73.93% +26.37% -100.30 0 Comment
dancon7 65.98 3/3/2017 Outperform 3Y $4.13 -76.39% +25.26% -101.66 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TRVN.